A Sex-specific View on Atherosclerosis From molecular plaque insights to innovative diagnostics ...

YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and ...

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a ...

The multi-modal approach leverages additional information from the patient's tumor sample, using Natera's AI models trained on long-term molecular and clinical outcomes from Natera's proprietary ...

DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer detection, today announced the appointment of Cindy Soriano as Chief ...

An Abuja-based medical expert, Dr Maryam Ahmed Almustapha, has raised an alarm over the potentially devastating effects of ...

BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of ...

GraftAssure technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx FDA IVD approval application 95% complete at yea ...

GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in ...

After a prenatal test revealed that she had cancer, Dr. Sara Teichholtz (shown here with her 4-year-old son) was treated at MSK for cholangiocarcinoma. Nearly three years later, she has no evidence of ...